Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6R6U

Crystal structure of human cis-aconitate decarboxylase

6R6U の概要
エントリーDOI10.2210/pdb6r6u/pdb
分子名称Cis-aconitate decarboxylase, (R,R)-2,3-BUTANEDIOL, SODIUM ION, ... (4 entities in total)
機能のキーワードimmunity, inflammatory response, innate immunity, antimicrobial, decarboxylase, cis-aconitate, itaconate, lyase
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計101880.06
構造登録者
Lukat, P.,Chen, F.,Saile, K.,Buessow, K.,Pessler, F.,Blankenfeldt, W. (登録日: 2019-03-28, 公開日: 2019-09-25, 最終更新日: 2024-11-06)
主引用文献Chen, F.,Lukat, P.,Iqbal, A.A.,Saile, K.,Kaever, V.,van den Heuvel, J.,Blankenfeldt, W.,Bussow, K.,Pessler, F.
Crystal structure ofcis-aconitate decarboxylase reveals the impact of naturally occurring human mutations on itaconate synthesis.
Proc.Natl.Acad.Sci.USA, 116:20644-20654, 2019
Cited by
PubMed Abstract: -Aconitate decarboxylase (CAD, also known as ACOD1 or Irg1) converts -aconitate to itaconate and plays central roles in linking innate immunity with metabolism and in the biotechnological production of itaconic acid by We have elucidated the crystal structures of human and murine CADs and compared their enzymological properties to CAD from Recombinant CAD is fully active in vitro without a cofactor. Murine CAD has the highest catalytic activity, whereas CAD is best adapted to a more acidic pH. CAD is not homologous to any known decarboxylase and appears to have evolved from prokaryotic enzymes that bind negatively charged substrates. CADs are homodimers, the active center is located in the interface between 2 distinct subdomains, and structural modeling revealed conservation in zebrafish and We identified 8 active-site residues critical for CAD function and rare naturally occurring human mutations in the active site that abolished CAD activity, as well as a variant (Asn152Ser) that increased CAD activity and is common (allele frequency 20%) in African ethnicity. These results open the way for 1) assessing the potential impact of human CAD variants on disease risk at the population level, 2) developing therapeutic interventions to modify CAD activity, and 3) improving CAD efficiency for biotechnological production of itaconic acid.
PubMed: 31548418
DOI: 10.1073/pnas.1908770116
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.705 Å)
構造検証レポート
Validation report summary of 6r6u
検証レポート(詳細版)ダウンロードをダウンロード

227111

件を2024-11-06に公開中

PDB statisticsPDBj update infoContact PDBjnumon